ExplainersPoster · 19 of 28
94% of What?
A percentage needs a label. 94% of what?
In the published BLUE-C study, Cologuard Plus detected 93.9% of cancers and 43.4% of advanced precancers in one screening round.
The evidence behind it
The full caption
The published BLUE-C analysis of next-generation stool DNA testing (Cologuard Plus) reported 93.9% colorectal-cancer sensitivity and 43.4% advanced-precancer sensitivity in one screening round. These round to 94% and 43%. About 57% of people who had advanced precancer tested negative. These are separate disease groups—not the probability of disease after a negative result. The published analysis differs from the FDA primary-effectiveness population.
BLUE-C was funded by Exact Sciences, maker of Cologuard Plus; multiple published-study authors were company employees. Single-round test performance does not establish lifetime screening outcomes.
Colonoscopy can find and remove detected precancerous polyps during the same exam. It can also miss lesions and has preparation, sedation, bleeding, perforation, and other burdens or risks. Stool-based screening remains a guideline-supported option; a positive stool test requires colonoscopy. Choose a screening plan you can complete with your clinician.
Medical images are labeled AI-generated illustrations.